| Hannah Huff, | |
|
333 S Madison St, Muncie, IN 47305-2465 | |
| (765) 286-7000 | |
| Not Available |
| Full Name | Hannah Huff |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 5 Years |
| Location | 333 S Madison St, Muncie, Indiana |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972166106 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01087816A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health Ball Memorial Hospital | Muncie, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Open Door Health Services, Inc. | 5890696603 | 30 |
News Archive
Think back to middle school biology class, when you learned that boys have an X and a Y chromosome inside each cell, and girls have two X's.
Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.
› Verified 9 days ago
| Entity Name | Open Door Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770510240 PECOS PAC ID: 5890696603 Enrollment ID: O20040115000592 |
News Archive
Think back to middle school biology class, when you learned that boys have an X and a Y chromosome inside each cell, and girls have two X's.
Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Huff, Po Box 1676, Muncie, IN 47308-1676 Ph: (765) 286-7000 | Hannah Huff, 333 S Madison St, Muncie, IN 47305-2465 Ph: (765) 286-7000 |
News Archive
Think back to middle school biology class, when you learned that boys have an X and a Y chromosome inside each cell, and girls have two X's.
Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.
Morphotek, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined with gemcitabine and docetaxel in the treatment of metastatic soft tissue sarcoma.
Genentech, a member of the Roche Group, today announced that the company submitted a New Drug Application for vemurafenib to the U.S. Food and Drug Administration for people with BRAF V600 mutation-positive metastatic melanoma, and that Roche submitted a Marketing Authorization Application to the European Medicines Agency for vemurafenib in the same indication.
› Verified 9 days ago
Shereene Grant, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 S Madison St, Muncie, IN 47305 Phone: 765-286-7000 Fax: 765-213-2769 | |
Mohammad S Bahrami, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3631 N Morrison Rd, Muncie, IN 47304 Phone: 765-281-3443 Fax: 765-286-4124 | |
Dr. Jeffrey C Bird, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 221 N Celia Ave, Muncie, IN 47303 Phone: 765-741-2999 Fax: 765-747-3175 | |
Dr. Jeremy J. Hunt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3600 W Bethel Ave, Muncie, IN 47304 Phone: 765-284-7738 Fax: 765-213-3713 | |
Gregory K Gahl, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3631 N Morrison Rd, Muncie, IN 47304 Phone: 765-281-3443 Fax: 765-286-4124 | |
Lisa Renee Clay, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 210 N Celia Ave, Muncie, IN 47303 Phone: 765-702-4633 | |
Dr. Ann Lorae Morris, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3025 N Oakwood Ave, Muncie, IN 47304 Phone: 765-286-0862 |